Genetic aetiologies for childhood speech disorder: novel pathways co-expressed during brain development

Antony Kaspi, PhD_{1,2}, Michael S. Hildebrand, PhD_{2,3}, Victoria E. Jackson, PhD_{1,2}, Ruth Braden, PhD₃, Olivia van Reyk, MSpPath₃, Tegan Howell, BSpPath₃, Simone Debono, BSpPath₃, Mariana Lauretta, MSpPath₃, Lottie Morison, MSpPath₃, Matthew Coleman, BSc (Hons)_{2,3}, Richard Webster, MBBS₄, David Coman, MBBS_{5,6}, Himanshu Goel, MBBS₇, Mathew Wallis, MBBS_{8,9}, Gabriel Dabscheck, MBBS_{2,10}, Lilian Downie, MBBS_{2,10}, Emma K. Baker, PhD _{2,3}, Bronwyn Parry-Fielder, BSpPath₁₀, Kirrie Ballard, PhD₁₁, Eva Harrold BSpPath₃, Shaun Ziegenfusz, MSpPath₁₂, Mark F. Bennett, PhD_{1,2}, Erandee Robertson, BSc (Hons)_{1,2}, Longfei Wang PhD_{1,2}, Amber Boys, BSc (Hons)₁₃, Simon E. Fisher, DPhil_{14,15}, David J. Amor, PhD_{2,3,10} Ingrid E. Scheffer, PhD₂, Melanie Bahlo*, PhD_{1,2}, Angela T. Morgan*, PhD_{2,3,6,10}

- 1. Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Victoria, Australia
- Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville 3052,
 Victoria, Australia
- 3. Murdoch Children's Research Institute, Parkville 3052, Australia
- 4. Neurology Department, The Children's Hospital at Westmead, Westmead 2145, New South Wales, Australia
- 5. Queensland Children's Hospital, South Brisbane 4101, Queensland, Australia
- 6. University of Queensland, St. Lucia 4067, Brisbane, Queensland, Australia

- 7. Hunter Genetics, John Hunter Hospital, New Lambton Heights 2305, New South Wales, Australia
- 8. School of Medicine and Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
- 9. Tasmanian Clinical Genetics Service, Hobart, TAS, Australia
- 10. Royal Children's Hospital, Flemington, Parkville, Melbourne, VIC, Australia
- 11. University of Sydney, Camperdown 2006, New South Wales, Australia
- 12. Griffith University, Gold Coast, Queensland, Australia
- 13. Victorian Clinical Genetics Services, Australia
- 14. Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen 6525 XD, The Netherlands
- 15. Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen 6500HE, The Netherlands

^{*}These authors contributed equally to the work

Abstract

Childhood apraxia of speech (CAS), the prototypic severe childhood speech disorder, is characterized by motor programming and planning deficits. Genetic factors make substantive contributions to CAS aetiology, with a monogenic pathogenic variant identified in a third of cases, implicating around 20 single genes to date. Here we ascertained 70 unrelated probands with a clinical diagnosis of CAS and performed trio genome sequencing. Our bioinformatic analysis examined single nucleotide, indel, copy number, structural and short tandem repeat variants. We prioritised appropriate variants arising de novo or inherited that were expected to be damaging based on *in silico* predictions. We identified high confidence variants in 18/70 (26%) probands, almost doubling the current number of candidate genes for CAS. Three of the 18 variants affected SETBP1, SETD1A and DDX3X, thus confirming their roles in CAS, while the remaining 15 occurred in genes not previously associated with this disorder. Fifteen variants arose de novo and three were inherited. We provide further novel insights into the biology of child speech disorder, highlighting the roles of chromatin organization and gene regulation in CAS, and confirm that genes involved in CAS are co-expressed during brain development. Our findings confirm a diagnostic yield comparable to, or even higher, than other neurodevelopmental disorders with substantial de novo variant burden. Data also support the increasingly recognised overlaps between genes conferring risk for a range of neurodevelopmental disorders. Understanding the aetiological basis of CAS is critical to end the diagnostic odyssey and ensure affected individuals are poised for precision medicine trials.

Introduction

Childhood apraxia of speech (CAS) is a rare neurodevelopmental disorder, occurring in 0.1% of

the population ¹. CAS stems from deficits in speech planning and programming, affecting a

child's ability to sequence sounds and syllables accurately and with correct prosody, resulting in

highly unintelligible speech ^{1, 2}. The first evidence implicating a specific gene in aetiology of

CAS was provided in 2001, via a family study revealing that pathogenic variants in FOXP2 were

responsible for the speech disorder ³. For almost two decades, FOXP2 was the only gene

associated with CAS, in the absence of intellectual disability. Technological advances and

reduced costs for DNA analyses have recently enabled efficient genome sequencing and

bioinformatic follow-up, paving the way for high throughput discovery of genes involved in

CAS. In particular, two independent cohort studies have performed genome-wide sequencing on

52 individuals with CAS ^{4, 5}.

In the first cohort, actiologic variants were identified in eight of 19 probands ascertained for

CAS, yielding a genetic diagnostic rate of 42% with pathogenic variants revealed in: CHD3,

SETD1A, WDR5, KAT6A, SETBP1, ZFHX4, TNRC6B and MKL2 4. In the second cohort,

comprising 33 probands with CAS, nine additional genes were implicated: CDK13, EBF3,

GNAO1, GNB1, DDX3X, MEIS2, POGZ, UPF2 and ZNF142. One individual also had a

contiguous gene deletion, yielding a genetic diagnostic rate of 33% (11/33) across this second

cohort ⁵. In these studies, there was no evidence of recurrent point mutations and no genes which

appeared to carry a higher burden of mutations, except for SETBP1; for which two individuals

were found to carry variants across the two cohorts ⁶.

Taken together, the two cohort studies provided novel insights into the neurobiology of childhood speech disorders. First, the discovery of 17 new genes involved in CAS actiology, with a combined diagnostic yield of 37%, revealing for the first time, that many children do have a single gene diagnosis explaining their speech condition. Second, many of the highly penetrant variants implicated shared pathways broadly involved in transcriptional regulation (e.g. POGZ, SETBP1, SETD1A, KAT6A), suggesting a key role for transcriptional dysregulation in aberrant speech development^{4, 5}. Other molecular pathways of significance were also were also revealed with high confidence and likely novel pathogenic variants, such as in GNA01 and GNB1, both part of G-protein signaling pathways ⁵. Third, the studies demonstrated that pathogenic variants more commonly arise de novo rather than being inherited, and that speech disorders are genetically heterogeneous ⁵, as is the case for other neurodevelopmental disorders ⁷⁻⁹. Fourth, the candidate genes newly implicated in CAS were frequently associated with other neurodevelopmental disorders, such as epilepsy (e.g. GNAO1, GNB1, SETD1A) and/or intellectual disability (e.g. CDK13, CHD3, DDX3X, POGZ, SETBP1) ^{4,5}. These novel insights into CAS aetiology, including genetic heterogeneity, demonstrate the need to study additional, larger cohorts to reveal further causative genes, increase the genetic diagnostic yield, and further unravel molecular pathways underlying severe childhood speech disorder. A much deeper knowledge of the molecular bases of severe speech conditions such as CAS is essential to move the field toward precision therapies.

Here, we aimed to identify molecular bases in a large cohort of probands ascertained for a primary diagnosis of CAS. Each proband underwent comprehensive phenotypic analysis and genome sequencing to identify pathogenic variants of major effect. We also analysed the

molecular co-expression of all genes associated with CAS, and the overlap of genes associated

with CAS and other neurodevelopmental disorders.

Methods

Ethical consent

The study was approved by the Human Research Ethics Committee of The Royal Children's

Hospital, Melbourne, Australia (#37353). Written informed consent was obtained from parents

or legal guardians to take part in the study and have the results of this study published.

Participants and phenotyping

Probands under age 18 years were ascertained with a clinical diagnosis of CAS and where

parents and clinicians reported the current primary clinical concern as poor speech development

⁵. Probands with moderate to severe intellectual disability were excluded. Participants were

recruited via medical and speech pathology clinicians or direct parent referral. Medical and

developmental history and secondary neurodevelopmental outcomes were recorded with

validation via relevant professional reports (e.g. paediatrician, multi-disciplinary assessment

team for ASD diagnosis, physiotherapist, occupational therapist, academic outcomes) (Tables 1,

2; Supplementary Table 1).

A diagnosis of CAS was based on meeting the three American Speech-Language-Hearing

Association consensus criteria for CAS: 1) inconsistent errors on consonants and vowels in

repeated productions of syllables or words; 2) lengthened and disrupted coarticulatory transitions

between sounds and syllables, and 3) inappropriate prosody ¹. Criteria were operationally defined

and rated ¹⁰ from phonetic transcriptions of standardised single word speech sub-tests

(phonology and inconsistency) ¹¹ and a 5-minute conversational speech sample ⁵. Dysarthria was

diagnosed in the presence of oral tone or coordination disturbance and dysarthric features

identified during conversation using the Mayo Clinic Dysarthria rating scale ^{12, 13}. Language and

cognition were also assessed with standardised tools ¹⁴⁻¹⁷.

Genetic testing

Genomic DNA was extracted from whole blood or saliva using a Qiagen (Valencia, CA)

QIAamp DNA Maxi kit or a prepIT L2P kit (DNA Genotek Inc., Ontario, Canada), respectively.

Probands underwent chromosomal microarray testing on Illumina (SanDiego, CA) platforms,

with the reportable effective resolution of arrays being 200 Kb. Results were analyzed with

Karyostudio software version 1.3 or 1.4 (Illumina), using genome reference sequence

NCBI36/hg18 (v1.3, pre-2013) or GRCh37/hg19 (v1.4, 2013 onwards).

Genome sequencing was conducted on 204 individuals from 70 families comprising 71 probands

(two probands were monozygotic twins hence for the genetic analysis and results we report on

70 probands), 127 parents and 6 other relatives. Illumina TruSeq DNA Nano or NovaSeq PE150

PCR free library preparation was completed prior to sequencing on the Illumina NovaSeq 6000

to average 30-fold depth with ~100Gb data generated per sample at the Australian Genome

Research Facility or Novogene (HK) Company Limited. Sanger sequencing or droplet digital

PCR (ddPCR) were used to segregate variants in additional family members who had not

undergone microarray or genome sequencing.

Variant analysis

Variant discovery was performed using trio or parent-child pair (where one parent was

unavailable for testing) designs (Fig. 1). Exceptions to this were two singletons, and four larger

families. 150 bp sequence pair-end reads were mapped to the hg19 reference genome using the

Burrow-Wheeler Aligner (BWA-MEM, bwa v0.7.17) 18. Read sorting and indexing was

undertaken using SAMtools (v1.9) and Genome Analysis Toolkit (GATK, v4.1.4.1) was used to

mark duplicates. Base quality score recalibration was performed, and variants were called using

HaplotypeCaller, with individuals called separately, as implemented by GATK. Sequencing

quality control was performed using fastQC.

Genotype calling and quality filtering were performed separately in multiple genome sequencing

batches. Joint calling was performed by merging per-sample gvcf files and applying GATK's

GenotypeGVCFs tool. Variants with excess heterozygosity (Z score >4.5) were removed, then

variant quality score recalibration was carried out for single nucleotide variants (SNVs) and

indels separately, with a truth sensitivity filter of 99.7 to flag variants for exclusion. Filtering of

low quality SNV calls excluded those flagged by low threshold or any of the following filters:

low quality by depth (QD <2); evidence of strand bias (Fisher strand [FS] >60 or strand odds

ratio [SOR] >3); and evidence of significant differences between alternate and reference alleles

for read mapping qualities (rank sum < -12.6) or position bias (ReadPosRankSum < -8). Indels

filtering was performed in a similar manner to missense variant filtering, with exceptions being

to exclude variants with FS >200; SOR >10; or ReadPosRankSum < -20. Finally, familial

relationships were confirmed using peddy ¹⁹. Filtering and other scripted analysis was conducted

using R version 3.5.2.

Analysis was restricted to variants: (1) not present in gnomAD or with gnomAD allele count ≤ 2 ,

(2) not present in unaffected family members from our cohort, and (3) potentially de novo, or

consistent with an appropriate inheritance model matching the phenotypic pedigree (e.g.

dominant, recessive). Compound heterozygous models were considered for variants present in

gnomAD with a mean allele frequency <0.05%. Only variants with read depth >10 and genotype

quality >20 in the proband and their sequenced family members were considered. Identified

variants were annotated with the variant effect predictor (VEP v93.3) algorithm, using the

assembly version GRCh37.p13 and categorized based on the following series of annotations.

Genome-wide analysis of LoF and predicted damaging missense

variants

We analyzed the genome sequencing data for loss of function (LoF) and predicted damaging

missense variants genome-wide. Predicted LoF candidates were defined by using VEP

annotations that were required to meet three criteria: (1) annotated as frameshift, stop or start

lost, stop gained, splice acceptor or donor variant, (2) in a gene predicted intolerant to LoF

variation (ExACpLI ≥0.9 or LoFtool <0.1), and (3) at least one of the following: (a) CADD

Phred score ≥20 predicted damaging, or (b) predicted to affect splicing (AdaBoost score ≥0.6 or

random forest score ≥0.6 using the dbscSNV VEP plugin). For frameshift variants, the variant

was only required to be in a LoF intolerant gene.

Predicted damaging missense variants had to meet at least three criteria: (1) PolyPhen-2

prediction as "probably" or "possibly damaging", (2) SIFT prediction as "deleterious" or

"deleterious low confidence", (3) a CADD Phred score ≥20 predicted damaging, or (4) a

missense tolerance ratio significantly different from 1 (false discovery rate <0.05).

Criteria for identification and reporting of candidate variants

We applied a two-stage approach for shortlisting candidate variants, from our identified LoF and

damaging missense variants: (1) we selected variants located within genes of interest, a gene list

collated based on several relevant criteria, informed by previous CAS studies^{4,5}, and described

below. Pathogenicity of these variants was assessed using the American College of Medical

Genetics (ACMG) guidelines, and via review by a clinical geneticist; (2) where no candidate

variant was identified, we then applied a genome-wide, wholly agnostic to gene, search for

candidate variants, to be followed up with ACMG and clinical geneticist review. The size of the

cohort and the inability to perform statistical analyses to implicate novel genes, such as via

burden analysis, necessitated the usage of these constraints.

We report candidate variants as follows:

1. High-confidence variants: LoF and predicted damaging missing variants, that were

classified with the American College of Medical Genetics (ACMG) guidelines as

pathogenic (class 5) or likely pathogenic (class 4) ²⁰, and where the phenotype associated

with the gene was consistent with that of the proband.

2. Low confidence variants: LoF and predicted damaging missing variants, that were either

classified as of uncertain significance (3) according to ACMG guidelines, or classified

likely pathogenic (class 4), but where the gene was not consistent with the proband's

phenotype, or otherwise lacked evidence for pathogenicity.

All reported variants were inspected with the Integrative Genome Viewer (v 2.7).

Collated list of genes of interest

The list of genes of interest, used in shortlisting candidate variants (n=2145 genes, Supplementary Table 2), was collated from the following sources: genes from recent CAS cohort studies ^{4, 5}(n=19 genes), or previously confirmed single genes implicated in CAS such as *FOXP2* or GRIN2A^{3, 21} (n=81). Additionally, high-confidence genes known to harbour pathogenic variants in intellectual disability (n=1399), epilepsy (n=611), autism spectrum disorder (ASD, n=131) and cleft palate (n=156), recognised by Victorian Clinical Genetics Services, were extracted from PanelApp using an application programming interface (https://panelapp.agha.umccr.org/) ²². High-confidence ASD-related genes from the Simons Foundation Autism Research Initiative database were also included ²³ (n=419). Finally, brainexpressed genes associated with primate-human accelerated evolution were included; this set comprised of 415 genes overlapping human accelerated regions (HARs) that are also significantly over-expressed in brain, compared to other tissues ²⁴, and 45 genes overlapping with HARs, that were find to be exclusively expressed in human brain cells, and not in other primates ²⁵. This final set of genes were included, as HARs have previously been implicated in ASD and cognitive development, and thus may be involved in the evolutionary development of speech.

Copy number and structural variants

Manta (regions up to 5Mb) ²⁶ (v 1.6.0) and qDNAseq (bin size 10kb with CNVs up to 5Mb) ²⁷ (v 1.18.0) were used to detect CNVs and other structural variants. Manta detects structural variants

based on abnormal alignment of read pairs. qDNAseq detects structural variants based on read depth. Variants occurring in more than two families were filtered out to avoid false positives due to technical artefact. SVAnnot (v 2.5) was used to annotate the variants, filtering by gnomAD SV abundance with SVs with frequency >0.05% excluded. Candidate structural variants were identified using the same approach as for SNVs, with pathogenicity assessed via ACMG

Variant validation

guidelines and clinical review.

High-confidence variants were validated using Sanger sequencing or ddPCR. For Sanger sequencing, gene variants were amplified using gene specific primers (oligonucleotide sequences available on request) designed to the reference human gene transcripts (NCBI Gene). Amplification reactions were cycled using a standard protocol on a Veriti Thermal Cycler (Applied Biosystems, Carlsbad, CA) at 60°C annealing temperature for 1 minute. Bidirectional sequencing of all exons and flanking regions was completed with a BigDye v3.1 Terminator Cycle Sequencing Kit (Applied Biosystems). Sequencing products were resolved using a 3730xl DNA Analyzer (Applied Biosystems). All sequencing chromatograms were compared to the published cDNA sequence; nucleotide changes were detected using Codon Code Aligner (CodonCode Corporation, Dedham, MA). For ddPCR, probes and primers were designed inhouse and synthesized by Integrated DNA Technologies (Coraville, IA) and assays were performed ^{28, 29}, using a Bio-Rad QX200 Droplet Digital PCR System (Hercules, CA) and OuantaSoft software v1.7.4.0917.

Analysis of novel sources of genetic contributions to CAS

Three forms of genetic analysis for CAS that have not been previously applied were undertaken:

(1) short tandem repeat (STR) analysis of both known and novel pathogenic repeats

(Supplementary Table 3); (2) examination of common variants implicated in ASD, cleft palate,

and word reading ability, and their relevance to CAS, via associations with polygenic risk scores

(PRS) and (3) estimation of mitochondrial gene abundance (see Supplementary methods).

Brain gene co-expression and gene set enrichment analysis

Gene co-expression analyses were undertaken for our high-confidence genes (n=18) and then

extended to include 16 genes previously implicated in CAS ^{4, 5}, totalling 34 genes. Analyses were

conducted using a Monte Carlo sampling approach 4,5 with data from the BrainSpan Atlas of the

Developing Human Brain 30 (Supplementary Table 4). Co-expression analyses were also

performed to prioritize genes of uncertain significance for CAS (see Supplementary methods).

Gene set enrichment analyses were undertaken using gene sets in Gene Ontology molecular

function, cellular component, and biological processes databases as well as Reactome pathway

databases ³¹. g:Profiler was used to test for gene set enrichment ³² with a Bonferroni-corrected p-

value threshold of 0.05 to determine pathways enriched for genes implicated in CAS.

Data availability

Data can be made available by contacting the corresponding author.

Results

Phenotypic data

The 71 probands (53 males, 18 females, 1 monozygotic twin pair) from the 70 families had an

average age of 5 years 7 months (range 2 years 2 months to 16 years 8 months). Phenotypic

information for the cohort is shown in Tables 1, 2; Supplementary Tables 1a, 1b. Pathogenic

variants were confirmed in 18 probands (12 males, 6 females; average age of 5 years 7 months)

(Tables 1, 2) as described further in the following section. The phenotypes of the probands with

(n = 18) versus without (n = 52) variants are presented in Fig. 2.

All probands were ascertained based on a clinical diagnosis of CAS. Following our speech

assessment protocol, 15 of the 18 probands with pathogenic variants had CAS in isolation (n = 7)

or co-occurring with other speech disorders (n = 8) (Table 1). Three probands (IDs 2, 5, and 6;

Table 1) had other severe speech disorder presentations (dysarthria, n = 1; phonological and

articulation disorder, n = 1; inconsistent phonological disorder, n = 1). Expressive language

disorder was implicated in 15/17 probands (mild, n = 1; moderate, n = 4; severe or unable to be

scored due to severity, n = 10; Fig. 2). One proband was minimally verbal and unable to

complete a valid expressive language assessment. Receptive language disorder was noted in

13/18 individuals (mild, n = 1; moderate, n = 3; severe, n = 9). Of those old enough to read and

write (> 5 years, n = 8), 8 had reading impairment, and 8 had spelling impairment. Two probands

with pathogenic variants (2/18, 11%; IDs 10, 18) had CAS accompanied by fine motor and

related linguistic deficits, but without other neurodevelopmental disorder diagnoses.

Of the 18 children identified to carry high confidence variants, 14 had formal cognitive assessment with profiles ranging from an average full-scale IQ (FSIQ) (n = 3), to borderline FSIQ results (n = 6), to mild intellectual disability (n = 5). For 3 children, FSIQ could not be calculated due to significant performance variation across verbal and nonverbal subscales, which is a common experience for children with severe speech production deficits. The remainder (n = 4) did not have IQ testing because concerns with learning or cognition had not been raised or pursued by the family or treating physician and children were attending mainstream childcare or school settings (IDs 13-16; IDs 13, 14, 16 were < 4 years of age when few children receive formal cognitive testing). Other features included neurodevelopmental diagnoses or features secondary to CAS including mild ASD (n = 2), difficulties with attention (n = 4), and anxiety and mood-related symptoms (n = 1). Dysmorphic features such as epicanthic folds and pointed chin (Table 1), rated by a clinical geneticist with 24 years of clinical experience, were present in just over half of the probands with high confidence variants (11/18). Gross motor (n = 16) and fine motor delays (n = 14) were common and associated with a slower trajectory in learning to ride a bicycle, balance appropriately, draw, write, and cut compared to typical peers. Two of the 18 children with pathogenic variants (IDs 1, 12) had a history of seizures.

Single nucleotide and indel variants

A high confidence variant was identified in 18/70 (26%) of probands (Table 3a, Fig. 3). These included three frameshift, two splice acceptor, six nonsense, and six missense variants, as well as one multiple exon duplication, and they were found in 18 different genes (*ARHGEF9*, *BRPF1*, *DDX3X*, *DIP2C*, *ERF*, *HRNPNK*, *KDM5C*, *PHF21A*, *PURA*, *RBFOX3*, *SETBP1*, *SETD1A*, *SETD1B*, *SHANK3*, *SPAST*, *TAOK2*, *TRIP12*, *ZBTB18*). All high-confidence variants were *de novo* except in *PURA*, *ERF* and *RBFOX3*, which were inherited (Table 3a, Fig. 3). Many of these

genes that we newly implicate in CAS, as well as genes previously described in earlier sequenced CAS cohorts^{4, 5} are also associated with other neurodevelopmental disorders (Fig. 4a

and Fig. 4b, Supplementary Table 5).

four were likely pathogenic ²⁰.

The 13 nonsense, splice-site, frameshift or exon duplication variants were all in genes intolerant to loss-of-function variation (*ARHGEF9*, *DDX3X*, *DIP2C*, *ERF*, *HNRNPK*, *KDM5C*, *PHF21A*, *RBFOX3*, *SETD1A*, *SETBP1*, *SHANK3*, *TRIP12*, *ZBTB18*), according to gnomADpLI or LoFtool scores (Table 3a). The five missense variants were all predicted to be damaging by at least three in silico tools (SIFT, PolyPhen, CADD, MTR). Four of the 18 high confidence variants (in *ERF*, *SETD1A*, *SHANK3* and *ZBTB18*) were recurrent, with these variants having been reported previously in individuals with neurodevelopmental disorders ³³⁻³⁷. The remaining 14 high-confidence variants have not been previously reported: of these, ten were pathogenic and

In five probands, we identified low confidence, LoF variants in genes predicted to be intolerant to haploinsufficiency (Table 3b, *ABCC11*, *ATP7B*, *CTDSPL2*, *ERCC6L*, *ZNF512B*). These variants are all predicted to cause loss of function of the gene; however at present, none of these genes are established to cause CAS or other neurodevelopmental disorders and therefore are variants of unknown significance. Of note, a frameshift variant in *ATP7B* of uncertain significance, was also identified in our previous CAS cohort ⁵; in the present cohort, the identified variant (proband 49) is shared with their father; however, both parents of this proband are affected by CAS, so the variant does not fully segregate with CAS status. Thus, the relevance of *ATP7B* in CAS remains unclear.

In eight probands (8/70; 11.4%), we report nine rare (gnomAD allele count <=2) low confidence, predicted damaging missense variants (Table 3c). These are a selected subset of predicted damaging variants, located in genes that were of relevance due to known disease significance, or biological relevance, but were of uncertain pathogenicity, or the gene was not consistent with the proband's phenotype. Two of the nine variants were in genes previously associated with speech and/or language disorders - *ROBO2*, and *ZFHX4*; however, one of these was inherited from an unaffected parent (*ROBO2*, Proband 52), and for the other, it was not possibly to determine whether the variant was de novo, as parental DNA was unavailable (*ZFHX4*, proband 43). The remaining seven variants were located in *CHD5*, *FGFR1*, *JARID2*, *MEF2C*, *RAPGEF2*, *TET3*, *UBQLN2* and *ZEB2*. For each of these, the variant was deemed to be of uncertain significance (ACMG), and/or the phenotype associated with the gene was not consistent with the proband's phenotype. For all probands without a high confidence variant, the remaining predicted damaging missing variants, identified though our genome-wide search, are listed in Supplementary Table 6.

Copy number and structural variation

There were no diagnostic findings on clinical microarray analysis. In one individual (ID18) a *de novo* pathogenic tandem 59,799bp duplication was identified in *TRIP12*, spanning exons 7 to 37 out of 42(NM_001348323.3). This duplication is predicted to disrupt the reading frame causing loss of function (Supplementary Fig. 1).

Analysis of novel sources of genetic contributions to CAS

No repeat expansion of either known or novel repeats were identified in the CAS probands.

The polygenic risk score analysis did not identify any statistically significant findings, with the

strongest trend being observed for ASD where probands were enriched for ASD risk, nearly

achieving nominal significance (Two sample t-test, p=0.054). The cleft palate PRS also showed

increased risk for CAS probands, but this was not significant (two sample t-test, p=0.226). Word

reading was also decreased in CAS probands (two sample t-test, p=0.123).

Mitochondrial abundance analyses identified two CAS probands with high confidence, likely

pathogenic variants in genes known to have mitochondrial function as outliers (DDX3X and

HNRNPK) but overall mitochondrial abundance did not appear to be a biomarker for CAS

overall (see Supplementary results, Supplementary Fig. 2A-C).

Brain gene co-expression and gene set enrichment analyses

The median absolute correlation between our 18 high-confidence genes was $|\rho| = 0.4194$ (Fig.

5A). Thirty-two of the 153 pairwise correlations were among the top 5% most highly correlated

gene pairs genome-wide $|\rho| > 0.647$, Fig. 5B), and there was evidence that this set of genes was

more highly co-expressed than expected by chance (p = 0.0038). Gene set enrichment analyses

of a subset of seven highly co-expressed genes (BRPF1, DIP2C, KDM5C, PHF21A, SETBP1,

SETD1A, SETD1B) indicate they are involved in chromatin organization (GO:0006325; p =

 1.238×10^{-3}). (Supplementary Table 7)

The median pairwise correlation of gene expression for the 34 genes (18 high-confidence genes from the current study and 16 genes previously implicated in CAS), was significantly higher than expected by chance (median $|\rho| = 0.4095$, $p = < 2 \times 10^{-4}$, Fig. 5D). Gene set enrichment analyses of the highly co-expressed cluster of 15 genes from the present study and past cohorts ^{4, 5} (Fig. 5C) further highlighted the significant over-representation of genes involved in chromatin organization (GO:0006325; Bonferroni-corrected $p = 2.304 \times 10^{-6}$) as well as transcriptional regulation (GO:0003676; Bonferroni-corrected $p = 1.103 \times 10^{-4}$, 25,396 sets tested, Supplementary Table 7).

Finally, our co-expression model was used to prioritize candidate genes, beyond our high confidence set. Firstly we re-examined the set of low-confidence variants identified in the present study (Table 3b and c), and variants of uncertain significance from our previous cohort.⁵ Amongst the low confidence findings in this paper, *TET3* was the only gene identified for proritization (FDR<0.1), while three genes identified in our previous cohort were prioritized (*BRWD3*, *MCMBP* and *ZKSCAN1*). All four prioritzed genes are associated with chromatin organization and/or DNA binding. Second, we sought to prioritize genes contained in each of 21 large copy number variant regions, identified through a literature search. All regions span multiple genes, and the associated phenotypes include speech disorder as an associated clinical feature (Supplementary Tables 8 and 9). Prioritization analysis identified at least one gene in each region (FDR <0.1), with more than one candidate for 18/21 regions (Table 4) (Fig. 4E). In several instances, the prioritized gene from our co-expression network had already been proposed as the likely causal gene (see Supplementary results).

biological mechanisms underpinning speech development.

Discussion

Our findings almost double the current number of genes implicated in susceptibility to CAS and provide further novel insights into the biology of childhood speech disorder. We identified high confidence variants, thereby providing a clinical genetic diagnosis, for 18 children ascertained for CAS, revealing 15 genes that have not previously been associated with severe speech disorder (*ARHGEF9*, *BRPF1*, *DDX3X*, *DIP2C*, *ERF*, *HRNPNK*, *KDM5C*, *PHF21A*, *PURA*, *RBFOX3*, *SETBP1*, *SETD1A*, *SETD1B*, *SHANK3*, *SPAST*, *TAOK2*, *TRIP12*, *ZBTB18*). We identified a clinical genetic diagnosis in one-quarter of individuals tested; a diagnostic yield comparable to or even higher than other neurodevelopmental disorders with substantial *de novo variant burden*³⁸. We provide independent confirmation with unrelated cases for three genes previously shown to have causative gene variants implicated in CAS; *SETD1A* ⁴, *DDX3X* ⁵ and *SETBP1* ^{5, 6}. We highlight chromatin organization and transcriptional regulation as critical

The high confidence variants in this study were all located in genes previously associated with other common neurodevelopmental phenotypes including epilepsy, intellectual disability and ASD ^{4, 5}. These complex speech and neurodevelopmental presentations match our current understanding of genes that have been associated with ASD, epilepsy and/or intellectual disability, where pleiotropy, or overlapping comorbid phenotypes, are common ³⁹. However, for 15 of the 18 genes, this is the first time they have been specifically associated with CAS. Our work highlights the current bias in the literature to gene discovery cohorts across intellectual disability, autism and epilepsy relative to speech disorder. Hence, we have expanded the phenotypic spectrum for a number of genes previously implicated in neurodevelopmental

disorders, linking them with a specific speech diagnoses, as well as markedly increasing the list

of genes that should be prioritized for clinical testing in individuals with CAS.

Probands for whom we could provide a genetic diagnosis had a higher proportion of motor,

language and cognitive impairments, secondary to the primary concern of CAS, compared to

those probands without genetic diagnoses. We provide preliminary evidence for a threshold

effect where monogenic conditions may be more likely when individuals with CAS have

additional neurodevelopmental conditions, although further work on larger cohorts is needed to

confirm this hypothesis. Only two probands (11%) with genetic diagnoses (SETD1B (ID10),

TRIP12 (ID18)) had CAS without co-occurring neurodevelopmental disorder diagnoses. These

findings expand the spectrum of phenotypes associated with these conditions. SETD1B has been

previously associated with epilepsy, intellectual disability and language delay, and TRIP12 has

been associated with non-syndromic intellectual disability 40. Our data suggest that monogenic

causes can underpin the less commonly occurring 'isolated' CAS phenotypes. We also reinforce

the observation that, just as recent reports have suggested there are no 'autism-(specific) genes,'

³⁹ it appears 'speech-specific' monogenic conditions are also rare. This has recently been

acknowledged for individuals with FOXP2 variants, where the phenotypic spectrum has been

expanded from a relatively specific speech condition to include learning difficulties in at least

some of the affected individuals ^{41, 42}.

In terms of the biological pathways associated with speech disorder, we found a significant over-

representation of perturbed chromatin and transcriptional regulation pathways, consistent with

prior studies 4, 5. The five chromatin-related genes habouring high confidence variants in the

current cohort were significantly co-expressed during brain development and are co-expressed with similar genes previously implicated in CAS ^{4, 5}. KDM5C encodes a histone demethylase involved in regulation of gene expression ⁴³ and DNA methylation ⁴⁴, and LoF mutations in this gene have been shown to cause intellectual disability in females ⁴⁵. BRPF1, encoding a histone acetyl transferase, has also been associated with intellectual disability and dysmorphic features ⁴⁶. SETD1A encodes a histone methyltranferase and has previously been associated with schizophrenia, intellectual disability, and speech and/or language delays³³. SETD1B is also a histone methyltransferase associated with neurodevelopmental disorder ⁴⁷. PHF21A is a member of the BRAF35/histone deacetylase complex that mediates repression of neuron-specific genes ⁴⁸ and has previously been associated with ASD and intellectual disability ⁴⁹. HNRNPK encodes an RNA-binding protein known to interact with many molecular partners in multiple processes that regulate gene expression: chromatin remodeling, transcription, and mRNA splicing, translation, and stability ⁵⁰. De novo truncating variants in HNRNPK have been shown to cause Au-Kline neurodevelopmental syndrome including intellectual disability, ADHD, speech impairment, cardiac anomalies and a variety of dysmorphic features ³⁷. These results support earlier findings ^{4, 5} that chromatin modifiers and transcriptional regulators are critical for speech development. More generally, chromatin modifiers play important roles in neurodevelopmental disorders as they are key regulators in progenitor expansion, differentiation, cell-type specification, migration and maturation, with early errors in chromatin remodelling known to impact development of brain networks.⁵¹

Other genes confirmed to harbour pathogenic variants in CAS and associated with chromatin organization and transcriptional regulation were not as highly co-expressed during brain

development. Among these, *DDX3X*, regulates gene splicing and is associated with neurodevelopmental disorders characterised by intellectual disability, ASD ⁵² and more recently, CAS⁵. *RBFOX3*, a gene showing neuron-specific expression, is also involved in splicing and has been associated with epilepsy aphasia syndrome and impaired language ⁵³. *PURA* is implicated in the control of both DNA replication and transcription ⁵⁴, and PURA syndrome is noted to include 'absent speech' as a feature of the condition ⁵⁵. *ZBTB18* encodes a transcriptional repressor shown to play a critical role in orchestrating brain development, and has been associated with non-syndromic intellectual disability⁵⁶.

The remaining candidate genes that we newly implicate in CAS (*TAOK2*, *SPAST* and *ARHGEF9*) encode proteins with distinct functions. *TAOK2* is located in the 16p11.2 deletion region, a well-recognised CNV associated with CAS, among other neurodevelopmental phenotypes ^{57, 58}. The protein encoded by *TAOK2* has established roles in dendrite growth and synapse development ⁵⁹. *ARHGEF9* encodes collybistin, a brain-specific guanine nucleotide exchange factor. The gene has also been implicated in X-linked epileptic encephalopathy and neurodevelopmental disorder, where there is skewed X-inactivation in favour of the abnormal X-chromosome ⁶⁰. Finally, *SPAST* promotes microtubule growth in the cytoskeleton, playing an important role in neuronal development, and has been implicated in spastic paraplegia with dysarthric speech ⁶¹. Although previous reports describing individuals with *SPAST* variants have not thoroughly characterised speech in the early years of life, it is possible that CAS was part of the early profile of such cases. A pattern of CAS alongside dysarthria is not uncommon in other genetic forms of severe speech disorder, for example in Koolen de Vries Syndrome, ⁶² *SETBP1*-haploinsufficiency disorder ⁶, or *EBF3*-related core motor disturbance and ataxia.⁵

Whilst we were able to attain a diagnostic rate of 26%, other highly penetrant risk variants may have remained hidden due to our strict definition of high confidence variants, which was largely based on ACMG guidelines. By definition, for an identified variant to be deemed high confidence, a causative link to relevant disorder must be already established. Hence it is likely that a proportion of our of our low confidence candidate variants are truly causal but currently lack sufficient evidence. Identification of additional variants in these low confidence genes in future cohorts of individuals with CAS would elevate these findings to declare these genes as true CAS genes. Currently, they provide candidate genes for future studies. We also performed an expanded variant identification analysis including short tandem repeats which yielded no hits, suggesting at this time, that they do not play a major role in CAS ^{63, 64}.

Our data confirm that a substantive proportion of children with CAS or related severe speech disorders may have a monogenic condition. As such CAS can be viewed as a critical clinical indicator for single gene disorders, due to its sensitivity as a rare phenotype (1 per 1000) ⁴, relative to more common speech diagnoses such as articulation or phonological disorder (1 in 20) ⁶⁵. While some individuals may have relatively 'specific' CAS in the absence of other neurodevelopmental disorders, our findings support the increasing overlap between genes conferring risk for a range of neurodevelopmental disorders including CAS, epilepsy, ASD and intellectual disability. This observation is important because well defined speech diagnoses are not typically reported in published clinical studies where the focus lies on other diagnoses like intellectual disability, epilepsy or ASD. If there is mention of speech or language impairment, the phrase 'speech delay' is typically used, which is a highly non-specific term that could imply

general language understanding or expression difficulties (e.g. semantic or syntactic issues), and

hence may not even be referring to 'speech' impairment itself (e.g. difficulty with producing

speech sounds) ¹². Thus, our work highlights the importance of specifically describing speech

phenotypes in genotype-phenotype correlation studies and in considering a core diagnosis of

CAS as a red flag for a monogenic condition. Understanding the aetiological basis of CAS is

critical to end the diagnostic odyssey, identify comorbidities and ensure patients are poised for

precision medicine trials.

Acknowledgments

The authors thank the families for participating in this study.

Study funding

This work was funded by a National Health and Medical Research Council (NHMRC) Centre of

Research Excellence Grant (CRE-SLANG; 1116976, AM, MH, IS, MB, DA, SEF) and an

NHMRC project grant (1160893, AM, MB, DA, MH, SEF). AM was supported by an NHMRC

Practitioner Fellowship (1105008) and Investigator grant (1195955). KB was supported by

Australian Research Council Future Fellowship (120100355). MB was supported by a NHMRC

Senior Research Fellowship (1102971) and a NHMRC Investigator grant (1195236). IS was

supported by an NHMRC Investigator grant (1172897). SEF is supported by the Max Planck

Society.

Additional funding was provided by the Independent Research Institute Infrastructure Support

Scheme and the Victorian State Government Operational Infrastructure Program.

Disclosure

The authors have no conflicts of interest to declare.

Supplementary information is available at Molecular Psychiatry's website

References

- 1. American Speech-Language-Hearing A. Childhood apraxia of speech [Technical report]. 2007.
- 2. Morgan AT, Murray E, Liégeois FJ. Interventions for childhood apraxia of speech. *Cochrane Database Syst Rev* 2018; **5:** CD006278.
- 3. Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. *Nature* 2001; **413**(6855): 519-523.
- 4. Eising E, Carrion-Castillo A, Vino A, Strand EA, Jakielski KJ, Scerri TS *et al.* A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development. *Mol Psychiatry* 2019; **24**(7): 1065-1078.
- 5. Hildebrand MS, Jackson VE, Scerri TS, Van Reyk O, Coleman M, Braden RO *et al.* Severe childhood speech disorder: Gene discovery highlights transcriptional dysregulation. *Neurology* 2020; **94**(20): e2148-e2167.
- 6. Morgan A, Braden R, Wong MMK, Colin E, Amor D, Liégeois F *et al.* Speech and language deficits are central to SETBP1 haploinsufficiency disorder. *Eur J Hum Genet* 2021; **29**(8): 1216-1225.
- 7. Lelieveld SH, Reijnders MRF, Pfundt R, Yntema HG, Kamsteeg E-J, de Vries P *et al.* Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat Neurosci* 2016; **19**(9): 1194-1196.
- 8. Stessman HAF, Xiong B, Coe BP, Wang T, Hoekzema K, Fenckova M *et al.* Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. *Nat Genet* 2017; **49**(4): 515-526.
- 9. Epi KC, Epilepsy Phenome/Genome P, Allen AS, Berkovic SF, Cossette P, Delanty N *et al.* De novo mutations in epileptic encephalopathies. *Nature* 2013; **501**(7466): 217-221.

- 10. Mei C, Fedorenko E, Amor DJ, Boys A, Hoeflin C, Carew P *et al.* Deep phenotyping of speech and language skills in individuals with 16p11. 2 deletion. *European Journal of Human Genetics* 2018; **26**(5): 676-686.
- 11. Dodd B, Zhu H, Crosbie S, Holm A, Ozanne A. *Diagnostic evaluation of articulation and phonology (DEAP)*. Psychology Corporation: London, 2002.
- 12. Braden RO, Amor DJ, Fisher SE, Mei C, Myers CT, Mefford H *et al.* Severe speech impairment is a distinguishing feature of FOXP1-related disorder. *Dev Med Child Neurol* 2021; **63**(12): 1417-1426.
- 13. Braden RO, Boyce JO, Stutterd CA, Pope K, Goel H, Leventer RJ *et al.* Speech, Language, and Oromotor Skills in Patients With Polymicrogyria. *Neurology* 2021; **96**(14): e1898-e1912.
- 14. Wiig EH, Secord WA, Semel E. *Clinical evaluation of language fundamentals: CELF-5*. Pearson2013.
- 15. Dumont R, Willis JO. Kaufman Assessment Battery for Children–Second Edition. *Encyclopedia of Special Education* 2008: 1196-1197.
- 16. Wechsler D. Wechsler Intelligence Scale for Children Fifth Edition: WISC-V.: Pearson, 2013.
- 17. Wechsler D. Wechsler preschool and primary scale of intelligence—fourth edition. *The Psychological Corporation San Antonio, TX* 2012.
- 18. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv* [*q-bioGN*] 2013.
- 19. Pedersen BS, Quinlan AR. Who's Who? Detecting and Resolving Sample Anomalies in Human DNA Sequencing Studies with Peddy. *Am J Hum Genet* 2017; **100**(3): 406-413.
- 20. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; **17**(5): 405-424.
- 21. Turner SJ, Mayes AK, Verhoeven A, Mandelstam SA, Morgan AT, Scheffer IE. GRIN2A: an aptly named gene for speech dysfunction. *Neurology* 2015; **84**(6): 586-593.
- 22. Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O *et al.* PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat Genet* 2019; **51**(11): 1560-1565.

- 23. Banerjee-Basu S, Packer A. SFARI Gene: an evolving database for the autism research community. *Dis Model Mech* 2010; **3**(3-4): 133-135.
- 24. Wei Y, de Lange SC, Scholtens LH, Watanabe K, Ardesch DJ, Jansen PR *et al.* Genetic mapping and evolutionary analysis of human-expanded cognitive networks. *Nat Commun* 2019; **10**(1): 1-11.
- 25. Khrameeva E, Kurochkin I, Han D, Guijarro P, Kanton S, Santel M *et al.* Single-cell-resolution transcriptome map of human, chimpanzee, bonobo, and macaque brains. 2020; **30**(5): 776-789.
- 26. Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M *et al.* Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics* 2016; **32**(8): 1220-1222.
- 27. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF *et al.* DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. *Genome Res* 2014; **24**(12): 2022-2032.
- 28. Hildebrand MS, Harvey AS, Malone S, Damiano JA, Do H, Ye Z *et al.* Somatic GNAQ mutation in the forme fruste of Sturge-Weber syndrome. *Neurol Genet* 2018; **4**(3): e236.
- 29. Damiano JA, Do H, Ozturk E, Burgess R, Kalnins R, Jones NC *et al.* Sensitive quantitative detection of somatic mosaic mutation in "double cortex" syndrome. *Epileptic Disord* 2017; **19**(4): 450-455.
- 30. Miller JA, Ding S-L, Sunkin SM, Smith KA, Ng L, Szafer A *et al.* Transcriptional landscape of the prenatal human brain. *Nature* 2014; **508**(7495): 199-206.
- 31. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A *et al.* The reactome pathway knowledgebase. *Nucleic Acids Res* 2020; **48**(D1): D498-D503.
- 32. Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A *et al.* Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. *Nature Protocols* 2019; **14**(2): 482-517.
- 33. Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J *et al.* Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. *Nat Neurosci* 2016; **19**(4): 571-577.
- 34. Popp B, Ekici AB, Thiel CT, Hoyer J, Wiesener A, Kraus C *et al.* Exome Pool-Seq in neurodevelopmental disorders. *Eur J Hum Genet* 2017; **25**(12): 1364-1376.

- 35. De Rubeis S, Siper PM, Durkin A, Weissman J, Muratet F, Halpern D *et al.* Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations. *Mol Autism* 2018; **9:** 31.
- 36. Twigg SRF, Vorgia E, McGowan SJ, Peraki I, Fenwick AL, Sharma VP *et al.* Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis. *Nat Genet* 2013; **45**(3): 308-313.
- 37. Au P, You J, Caluseriu O, Schwartzentruber J, Majewski J, Bernier F *et al.* Care for Rare Canada, C, Valle D., Parboosingh JS et al. GeneMatcher aids in the identification of a new malformation syndrome with intellectual disability, unique facial dysmorphisms, and skeletal and connective tissue abnormalities caused by de novo variants in HNRNPK. *Hum Mutat* 2015; **36:** 1009-1014.
- 38. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D *et al.* The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014; **515**(7526): 216-221.
- 39. Myers SM, Challman TD, Bernier R, Bourgeron T, Chung WK, Constantino JN *et al.* Insufficient Evidence for "Autism-Specific" Genes. *Am J Hum Genet* 2020; **106**(5): 587-595.
- 40. Donoghue T, Garrity L, Ziolkowski A, McPhillips M, Buckman M, Goel H. Novel de novo TRIP12 mutation reveals variable phenotypic presentation while emphasizing core features of TRIP12 variations. *American Journal of Medical Genetics Part A* 2020; **182**(7): 1801-1806.
- 41. Reuter MS, Riess A, Moog U, Briggs TA, Chandler KE, Rauch A *et al.* FOXP2 variants in 14 individuals with developmental speech and language disorders broaden the mutational and clinical spectrum. *J Med Genet* 2017; **54**(1): 64-72.
- 42. Morgan A, Fisher SE, Scheffer I, Hildebrand M. FOXP2-related speech and language disorders. In: Pagon RAA, M. P; Ardinger H. H; Wallace, S. E; Amemiya, A; Bean, L. J. H; Bird, T. D; Fong, C, T; Mefford, H. C; Smith R. J. H; Stephens, K. (ed). *GeneReviews*: Seattle, Washington, 2017.
- 43. Brookes E, Laurent B, Õunap K, Carroll R, Moeschler JB, Field M *et al.* Mutations in the intellectual disability gene KDM5C reduce protein stability and demethylase activity. *Hum Mol Genet* 2015; **24**(10): 2861-2872.
- 44. Aref-Eshghi E, Kerkhof J, Pedro VP, Groupe DIF, Barat-Houari M, Ruiz-Pallares N *et al.* Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders. *Am J Hum Genet* 2020; **106**(3): 356-370.

- 45. Ounap K, Puusepp-Benazzouz H, Peters M, Vaher U, Rein R, Proos A *et al.* A novel c.2T > C mutation of the KDM5C/JARID1C gene in one large family with X-linked intellectual disability. *Eur J Med Genet* 2012; **55**(3): 178-184.
- 46. Mattioli F, Schaefer E, Magee A, Mark P, Mancini GM, Dieterich K *et al.* Mutations in Histone Acetylase Modifier BRPF1 Cause an Autosomal-Dominant Form of Intellectual Disability with Associated Ptosis. *Am J Hum Genet* 2017; **100**(1): 105-116.
- 47. Roston A, Evans D, Gill H, McKinnon M, Isidor B, Cogné B *et al.* SETD1B-associated neurodevelopmental disorder. *J Med Genet* 2021; **58**(3): 196-204.
- 48. Hakimi M-A, Bochar DA, Chenoweth J, Lane WS, Mandel G, Shiekhattar R. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. *Proc Natl Acad Sci U S A* 2002; **99**(11): 7420-7425.
- 49. Kim H-G, Rosenfeld JA, Scott DA, Bénédicte G, Labonne JD, Brown J *et al.* Disruption of PHF21A causes syndromic intellectual disability with craniofacial anomalies, epilepsy, hypotonia, and neurobehavioral problems including autism. *Mol Autism* 2019; **10**(1): 35.
- 50. Fukuda T, Naiki T, Saito M, Irie K. hnRNP K interacts with RNA binding motif protein 42 and functions in the maintenance of cellular ATP level during stress conditions. *Genes to Cells* 2009; **14**(2): 113-128.
- 51. Mossink B, Negwer M, Schubert D, Nadif Kasri N. The emerging role of chromatin remodelers in neurodevelopmental disorders: a developmental perspective. *Cell Mol Life Sci* 2021; **78**(6): 2517-2563.
- 52. Beal B, Hayes I, McGaughran J, Amor DJ, Miteff C, Jackson V *et al.* Expansion of phenotype of DDX3X syndrome: six new cases. *Clin Dysmorphol* 2019; **28**(4): 169-174.
- 53. Turner SJ, Morgan AT, Perez ER, Scheffer IE. New genes for focal epilepsies with speech and language disorders. *Curr Neurol Neurosci Rep* 2015; **15**(6): 35.
- 54. Hunt D, Leventer RJ, Simons C, Taft R, Swoboda KJ, Gawne-Cain M *et al.* Whole exome sequencing in family trios reveals de novo mutations in PURA as a cause of severe neurodevelopmental delay and learning disability. *J Med Genet* 2014; **51**(12): 806-813.
- 55. Reijnders MRF, Leventer RJ, Lee BH, Baralle D, Selber P, Paciorkowski AR *et al.* PURA-Related Neurodevelopmental Disorders. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G *et al.* (eds). *GeneReviews*®. University of Washington, Seattle: Seattle (WA), 2017.

- 56. van der Schoot V, de Munnik S, Venselaar H, Elting M, Mancini GMS, Ravenswaaij-Arts CMA *et al.* Toward clinical and molecular understanding of pathogenic variants in the ZBTB18 gene. *Mol Genet Genomic Med* 2018; **6**(3): 393-400.
- 57. Fedorenko E, Morgan A, Murray E, Cardinaux A, Mei C, Tager-Flusberg H *et al.* A highly penetrant form of childhood apraxia of speech due to deletion of 16p11.2. *Eur J Hum Genet* 2016; **24**(2): 302-306.
- 58. Mei C, Fedorenko E, Amor DJ, Boys A, Hoeflin C, Carew P *et al.* Deep phenotyping of speech and language skills in individuals with 16p11.2 deletion. *Eur J Hum Genet* 2018; **26**(5): 676-686.
- 59. de Anda FC, Rosario AL, Durak O, Tran T, Gräff J, Meletis K *et al.* Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex. *Nat Neurosci* 2012; **15**(7): 1022-1031.
- 60. Alber M, Kalscheuer VM, Marco E, Sherr E, Lesca G, Till M *et al.* ARHGEF9 disease. *Neurology Genetics* 2017; **3**(3).
- 61. Ogasawara M, Saito T, Koshimizu E, Akasaka N, Sasaki M. A p.Arg499His Mutation in SPAST Is Associated with Infantile Onset Ascending Spastic Paralysis Complicated with Dysarthria and Anarthria. *Neuropediatrics* 2019; **50**(6): 391-394.
- 62. Morgan AT, van Haaften L, van Hulst K, Edley C, Mei C, Tan TY *et al.* Early speech development in Koolen de Vries syndrome limited by oral praxis and hypotonia. *Eur J Hum Genet* 2018; **26**(1): 75-84.
- 63. Folker JE, Murdoch BE, Rosen KM, Cahill LM, Delatycki MB, Corben LA *et al.* Differentiating profiles of speech impairments in Friedreich's ataxia: a perceptual and instrumental approach. *Int J Lang Commun Disord* 2012; **47**(1): 65-76.
- 64. Chan JCS, Stout JC, Vogel AP. Speech in prodromal and symptomatic Huntington's disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases. *Neurosci Biobehav Rev* 2019; **107**: 450-460.
- 65. Reilly S, McKean C, Morgan A, Wake M. Identifying and managing common childhood language and speech impairments. *BMJ* 2015; **350:** h2318.
- 66. Kohlenberg TM, Trelles MP, McLarney B, Betancur C, Thurm A, Kolevzon A. Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. *J Neurodev Disord* 2020; **12**(1): 7.

Figure Legends

Fig. 1. Genetic variant identification and variant filtering pipeline for individuals with CAS

Workflow covers recruitment of patients (CAS in red, affected relative in blue, unaffected in

black), DNA sequencing, analysis and filtering of genomic data, identification of potential

causative variants, geneticist review, molecular validation, segregation and integration of all

findings. *Only the damaging effects of small variants are predicted bioinformatically.

Fig. 2: Phenotypic overlap in childhood apraxia of speech (CAS) cohort

Phenotypic features of CAS cohort with (n=18) and without (n=52) pathogenic variants. Data

based on children with formal assessments by health professionals (i.e., cognition, language,

motor, formal ASD diagnoses). Data from Tables 1, 2; Supplementary Tables 1a, 1b.

Fig. 3. Families with High Confidence Variants analysed by genome sequencing

Families analysed by Genome Sequencing. Pedigrees (A-F, M-R, Y, A1, C1, E1, G1, I1) from

18 families with 18 different high confidence variants. Sequence chromatograms (G, I, J, L, S, T,

V, W, X, Z) showing de novo or inherited variants. Sanger sequencing was not performed for the

variants in eight of the families (B, E, O, A1, C1, E1, G1, I1).

Fig. 4: Previously identified neurodevelopmental conditions in candidate genes for CAS

(A) Candidate Genes for CAS identified in this study and Hildebrand et. al. (*) also have been shown to cause other neurodevelopmental disorder traits. (B) Venn diagram showing the overlap of these genes and multiple neurodevelopmental disorder traits.

Fig. 5: CAS candidate gene co-expression

(A) Gene co-expression matrix for the 18 high-confidence candidate genes with pairwise

Spearman's rank correlation coefficients between genes shown, based on 280 samples from 24

individuals (8 weeks post conception to 10 months after birth) from the BrainSpan resource.

Genes ordered by hierarchical clustering, using the median linkage method. (B) Network of gene

co-expression. Nodes represent genes; edges represent gene-pair correlations that exceed the

threshold for the top 5% most highly correlated gene pairs genome-wide ($|\rho| > 0.64$) (blue –

positive correlation, red - negative correlation). (C) Gene co-expression matrix for the 18 high-

confidence novel candidate genes (black) as well as the genes from 4 (green) and 5 (blue). (D)

Network of gene co-expression. Nodes represent genes; edges represent gene-pair correlations

that exceed the threshold for the top 5% most highly correlated gene pairs genome-wide ($|\rho|$ >

0.64) (blue – positive correlation, red – negative correlation). Black nodes - novel genes from

this work, green nodes genes from ⁴ and blue nodes from ⁵ (E) Network of gene co-expression.

Nodes represent genes; edges represent gene-pair correlations that exceed the threshold for the

top 5% most highly correlated gene pairs genome-wide ($|\rho| > 0.64$) (blue – positive correlation,

red – negative correlation). Black nodes are a set of co-expressed genes including novel genes

from this work as well as those from earlier works^{4, 5}. Blue nodes - the top prioritized genes

variants

described

in

Table

4.

from

cytogenic

medRxiv preprint doi: https://doi.org/10.1101/2022.05.15.22274630; this version posted May 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 1: Medical and neurodevelopmental features of individuals with CAS and pathogenic/likely pathogenic variants

Family	Age, y;m	Sex	Core speech phenotype	Gene	Gross motor delay	Fine motor delay	Vision impaired #	Hearing loss#	MRI findings [#]	Seizures#	Other NDD#	Dysmorphic features#	Other medical [#]
1	15- 17	F	CAS	ARHGEF9	Y	Y							
2	6-8	F	Dysarthria	DDX3X	Y	Y							
3	6-8	F	CAS	KDM5C	N	N							

4	6-8	M	CAS	PHF21A	Y	Y				
4	0-8	IVI	CAS	THEZIA	1	1				
5	3-5	M	Inconsistent	BRPF1	Y	N				
	3 3	111	phonological		1	11				'
			dologod							
			delay and disorder							
			disorder							
6	6-8	F	Phonological disorder,	PURA	Y	Y				
			disorder,							
			articulation							
			disorder							
-	2.5	3.6	CAC	ZBTB18	3.7	37				
7	3-5	M	CAS	ZBIBIO	Y	Y				
		_	G . G	THIRD LIBER						
8	3-5	F	CAS	HNRNPK	Y	Y				
9	6-8	М	CAC	SETD1A	Y	Y				
y	0-8	M	CAS,	SEIDIA	Y	Y				
			phonological disorder							
			disorder							
		<u>i</u>	1	1	1	1				

10	9-11	M	CAS, phonological error patterns	SETD1B	Y	Y				
11	3-5	M	CAS, phonological error patterns	RBFOX3	Y	Y				
12	3-5	M	CAS, phonological error patterns	TAOK2	Y	Y				
13	0-1	M	CAS, minimally verbal	SPAST	Y	N				
14	3-5	M	CAS, minimally verbal	SHANK3	Y	Y				
15	6-8	M	CAS, phonological delay	DIP2C	Y	Y				
16	3-5	М	CAS	SETBP1	Y	Y				
17	6-8	F	CAS, Dysarthria	ERF	Y	Y				

18	3-5	M	CAS	TRIP12	N	N				

NDD, Neurodevelopmental disorder; ASD, Autism spectrum disorder; CAS, Childhood apraxia of speech; DCD, Developmental coordination disorder; F, Female; ID, Intellectual disability; M, Male; N, Feature not present; SPD, Sensory processing disorder; Y, Feature present, *These details have been removed to avoid the identification of patients, *Ages have been denoted in 2-year bands to avoid the identification of participants

medRxiv preprint doi: https://doi.org/10.1101/2022.05.15.22274630; this version posted May 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 2: Linguistic phenotype and educational setting of individuals with CAS and pathogenic/likely pathogenic variants

Family	Oral motor impairment	History of feeding issues	Language: receptive*	Language: expressive*	Reading deficits	Spelling deficits	Speech pathology	IQ#	Education setting
1	Y	Y	Severe	Severe	Y	Y	Y		Specialist
2	Y	Y	Severe	Severe	Y	Y	Y		Mainstream (with classroom support)
3	Y	Y	Moderate	Severe	Y	Y	Y		Mainstream
4	Y	N	Severe	Severe	Y	Y	Y		Mainstream
5	Y	Y	Average	Moderate	TY	TY	Y		Mainstream
6	Y	Y	Severe	NA	Y	Y	Y		Mainstream (with classroom support)
7	Y	Y	Severe	Severe	TY	TY	Y		Mainstream
8	Y	Y	NS	NS	TY	TY	Y		Not yet at school
9	Y	N	Moderate	Moderate	Y	Y	Y		Mainstream
10	Y	N	Average	Average	Y	Y	Y		School for children with specific speech and language impairments
11	Y	N	Mild	Moderate	TY	TY	Y		Mainstream

12	Y	N	Severe	Mild	TY	TY	Y	Specialist
13	Y	N	Average	Severe	TY	TY	Y	Mainstream
14	Y	Y	Severe	Severe	TY	TY	Y	Mainstream
15	Y	N	Average	Moderate	Y	Y	Y	Mainstream
16	Y	N	Severe	Severe	TY	TY	Y	Mainstream
17	Y	Y	Moderate	Severe	TY	TY	Y	Mainstream
18	Y	N	Average	Average	TY	TY	Y	Mainstream

FSIQ, Full scale IQ; N, No; NA, Not assessed; VCI: Verbal Comprehension Index; VSI: Visual Spatial Comprehension; GMDS: Griffiths

Mental Developmental Scales; WNV: Weschler non-verbal scale of ability; KBIT: Kaufman Brief Intelligence Test; PRI, Perceptual reasoning index; TY, not applicable for literacy testing as pre-school age (< 5 years old); Y, feature present.

^{*}Language severity rated according to CELF-5¹⁴ as follows: 86-114 average, 78-85 mild, 71-77 moderate, <70 severe.

[^] Assessment not previously indicated by the family or treating physician at time of study.

[#]These details have been removed to avoid the identification of patients.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.15.22274630; this version posted May 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

a: High-confidence gene variants in individuals with CAS

Table 3

Family	Sex	Chr:Pos	Gene	OMIM	DNA Variant	Protein Change	Effect	In Silico Predictions ^{\$}	gnomAD Count ~	Inheritan ce	ACMG score	Reference *
1	F	X:62885786	ARHGEF9	616056	c.1036C>T	p.Q346*	Nonsense	gnomADpLI = 0.98; LoFtool = 0.0652; CADD= 38	0	De novo	PVS1, PS2, PM2, PP3 Class 5 Pathogenic	
2	F	X:41201905	DDX3X	300958	c.442C>T	p.Q148*	Nonsense	gnomADpLI = 1 LoFtool = 0.0555; CADD= 43	0	De novo	PVS1, PM2, PP3 Class 5 Pathogenic	
3	F	X:53231113	KDM5C	300534	c.1787_1788delC C	p.T596IfsTer2	Frameshift	gnomADpLI = 1; LoFtool = 0.0636;	0	De novo	PVS1, PS2, PM2, PP3 Class 5 Pathogenic	
4	M	11:45975138	PHF21A	608325	c.1029_1032delA ACA	p.T344RfsTer 28	Frameshift	gnomADpLI = 1; LoFtool = 0.08;	0	De novo	PVS1, PS2, PM2, PP3 Class 5 Pathogenic	
5	M	3:9788123	BRPF1	617333	c.3464A>T	p.D1155V	Missense	SIFT = Del(0); PolyPhen = Dam (0.99); CADD= 33	0	De novo	PS2, PM2, PP3, BP1 Class 4 Likely Pathogenic	
6	F	5:139494062	PURA	616158	c.296G>T	p.R99L	Missense	SIFT = Del(0); PolyPhen = Dam (0.984); CADD= 28.7	0	Inherited from affected mother	PM2, PP1, PP2, PP3 Class 4 Likely Pathogenic	
7	M	1:244217218	ZBTB18	612337	c.142C>T	p.R48*	Nonsense	gnomADpLI = 1 LoFtool = 0.18; CADD= 36	0	De novo	PVS1, PS2, PM2, PP3, PP5 Class 5 Pathogenic	34

8	F	9: 86585096	HNRNPK	616580	c.1342C>T	p.Q448*	Nonsense	gnomADpLI = 1 CADD= 43	0	De novo	PS2, PM2, PP3. Class 5 Pathogenic	
9	M	16:30992057	SETD1A	619056	c.4582-2delAG	NA	Splice Acceptor Site	gnomADpLI = 1 LoFtool = 0.00654; CADD= 24.6	2	De novo	PVS1, PS2, PM2, PP3 Class 5 Pathogenic	33
10	М	12:22265722	SETD1B	619000	c.5551G>A	p.E1851K	Missense	SIFT = Del(0); PolyPhen = Dam (1); CADD= 33	0	De novo	PS2, PM1, PM2, PP2, PP3 Class 5 Pathogenic	
11	М	17:77097708	RBFOX3	616999	c.526C>T	p.R176*	Nonsense	gnomADpLI = 1 LoFtool = 0.17; CADD= 46	0	Inherited from affected father	PVS1, PM2, PP1 Class 5 Pathogenic	
12	M	16:29996607	TAOK2	613199	c.1496G>A	p.R499Q	Missense	SIFT = Del(0.01); PolyPhen = Dam (0.992); CADD= 32	0	De novo	PS2, PM2, PP3, BP1 Class 4 Likely Pathogenic	
13	M	2:32352078	SPAST	182601	c.1160G>A	p.G387E	Missense	SIFT = Del(0); PolyPhen = Dam (1); CADD= 32	0	De novo	PS2, PM1, PM2, PP2, PP3 Class 5 Pathogenic	
14	М	22:51160325	SHANK3	606232	c.4290_4291del	p.V1432Gfs*4	Frameshift	gnomADpLI =1 CADD=35	0	De novo	PVS1, PS2, PM2, PP3, PP5 Class 5 Pathogenic	66
15	M	10: 323518	DIP2C	611380	c.4362-1G>A	NA	Splice Acceptor Site	gnomADpLI =1 LoFtool =0.356; CADD= 26.1	0	De novo	PVS1, PS2, PM2, PP3 Class 5 Pathogenic	
16	M	18: 42530578	SETBP1	611060	c.1273A>T	p.K425*	Nonsense	gnomADpLI = 1 LoFtool = 0. 0.0297; CADD= 38	0	De novo	PVS1, PS2, PM2, PP3 Class 5 Pathogenic	

17	M	19:42753717	ERF	617180	c.547C>T	p.R183*	Nonsense	gnomADpLI = 0.99 LoFtool = 0. 0.02; CADD= 35	0	Inherited from affected Mother	PVS1, PM2, PP1, PP5 Class 5 Pathogenic
18	F	2:230641603- 230701402du p	TRIP12	617752	NA	NA	Exonic duplication	gnomADpLI = 1	0	De novo	PVS1, PS2, PM2, PP3, PP5 Class 5 Pathogenic

b: Low confidence, predicted LoF variants in individuals with CAS

Famil y	Sex (M/F)	Chr:Pos	Gene	DNA Variant	Protein Change	Effect	In Silico Predictions ^{\$}	gnomAD Count ~	Inheritance	ACMG score
34	F	X:71424983	ERCC6L	c.3632_3633del	p.K1211R fs*14	Frameshift	gnomADpLI = 0.99 LoFtool = 0.0101; CADD= 35	1	Maternal	PM2, PP3. Uncertain significance
39	M	15:44789223	CTDSPL2	c.771-2A>G	NA	Splice Acceptor Site	gnomADpLI = 1 LoFtool = 0.0922; CADD=34; adaScore=0.9 99; rf_score=0.92	0	Unknown	PM2, PP3. Uncertain significance
49	M	13:52532500	ATP7B	GGGGCGTGT CGAAGAATG TCACA>G	NA	Frameshift	LoFtool = 0.034	0	Inherited from Father	PM2, PP3. Uncertain significance

50	M		CA>C	NA	Frameshift	LoFtool =	0	Inherited	PM2, PP3.
						0.015		from Father	Uncertain significance
		16:48247438 ABCC11							51 S
56	M		CT>C	NA	Frameshift	gnomADpLI	0	Inherited	PM2, PP3.
						=1		from Father	Uncertain
		20 (250077)							significance
		20:62598776 ZNF512B							

c: Low confidence, predicted damaging Missense variants in individuals with CAS

Fami ly	Sex (M/	Chr:Pos	Gene	DNA Variant	Protein Change	Effect	In Silico Predictions ^{\$}	gnomAD Count ~	Inherita nce	ACMG score
13	F)			v an iant	Change		Treaterons	Count	nec	Score
19	M	4:160251101	RAPGEF2	c.758C>T	p.M253T	Missense	SIFT = Del(0.01); PolyPhen = Ben (0.186); CADD= 23.2	0	De novo	PS2, PM2, PP3 Class 4 Likely Pathogenic
22	M	2:145156800	ZEB2	c.1954T>C	p.Y652H	Missense	SIFT=del(0.05), PolyPhen= PosDam(0.737), CADD=25.9	0	Inherited from Father	PM2,PP3,BP 1 Uncertain significance
28	M	8: 38271461	FGFR1	c.2360G>T	p.R787L	Missense	SIFT=del(0), PolyPhen= ProbDam(0.998), CADD=33	0	Inherited from Father	PM1, PM2, PP2, PP3 Likely Pathogenic

30	M	X:56591124	UBQLN2	c.818C>T	p.T273I	Missense	SIFT=del(0.01), PolyPhen= ProbDam(0.988),	0	Inherited from Mother -	PM2,PP2,PP 3 Uncertain significance
							CADD=26.9		X-linked	significance
43	M	8:77617377	ZFHX4	c.1054A>G	p.N352D	Missense	SIFT=delLowCon f(0.03), PolyPhen= ProbDam(0.991), CADD=26	2	Unknow n (parents not available	PM2,BP1 Uncertain significance
50	M	5:88056897	MEF2C	c.364G>T	p.D122Y	Missense	SIFT=del(0), PolyPhen= ProbDam(0.998), CADD=29.2	1	Inherited from Mother	PM2,PP2,PP 3 Uncertain significance
50	M	2:74314988	TET3	c.2711T>C	p.L904P	Missense	SIFT=del(0.01), PolyPhen= ProbDam(0.996), CADD=25.9	0	Inherited from Father	PM1,PM2, PP2,PP3 Likely Pathogenic
52	M	3:77530328	ROBO2	c.625G>A	p.V209 M	Missense	SIFT=del(0.03), PolyPhen= ProbDam(1), CADD=25.9	0	Inherited from Father	PM2,PP3,BP 1 Uncertain significance
53	M	6:15497248	JARID2	c.1792G>A	p.E598K	Missense	SIFT=del(0), PolyPhen= Ben(0.225), CADD=25.9	0	Inherited from Mother	PM2,PP3,BP 1 Uncertain significance

OMIM: Online Mendelian Inheritance in Man; ACMG: American College of Medical Genetics; NA, not applicable. All coordinates correspond to the Homo sapiens (human) genome assembly GRCh37 (hg19) from Genome Reference Consortium. § *In silico* pathogenicity predictions: SIFT (sorting intolerant from tolerant), scores <0.05 reported, Del="Deleterious"; PolyPhen-2, scores >0.15 reported, Dam="Damaging", PosDam="Possibly Damaging"; CADD (Combined Annotation Dependent Depletion), gnomADpLI (The Genome Aggregation Database

(gnomAD) probability of intolerance to LoF), scores >0.9 reported; LoFTool, scores <0.1 reported. ~ Number of alleles for variant from gnomAD or gnomAD SV for structural variants * Previously reported variant.

Table 4. Genes prioritized in cytogenetic regions which have previously been identified with speech and language disorders

Region	Prioritized Genes
1q21.1	BCL9 (13.4)
microdeletion	
2p15	UGP2 (8.6), USP34 (5.9), PEX13 (5.3)
5q14.3	RASA1 (8.1)
5q14q21.1	CHD1 (7.4)
6q25.3	ARID1B (12.2), TULP4 (6.9)
	GTF2IRD1 (11.5), BAZ1B (10.1),
7q11.23	RSBN1L (8.4), GTF2I (7.6), RHBDD2 (5.7)
7q31.1	CTTNBP2 (5.5)
7q31.2-q31.31	CTTNBP2 (5.5)
10q21.2-22.1	JMJD1C (8.5), CISD1 (8.1)
15q14	SLC12A6 (10.6), ANP32AP1 (5.7)
12p13.33-	KDM5A (8.9), ERC1 (8.1)
p13.32	
15q14	SLC12A6 (10.6), ANP32AP1 (5.7)
15q26.3	IGF1R (11.2)
	ZNF629 (11.5), SRCAP (10.8), ZNF764 (10.5),
	ZNF646 (10.4), SETD1A (9), ZNF48 (6.9),
16p11.2	ALDOA (6.4), ATXN2L (5.8)
16p11.2	ALDOA (6.4)
microdeletion	
16p13.2	USP7 (6.9)
17p11.2	USP22 (10.8), MAPK7 (10), TOP3A (9.4),

	SMCR8 (8.9), RAI1 (8.3), DHRS7B (7.9),
	TRPV2 (6.7)
	GPATCH1 (8.8), CEP89 (8.3), SLC7A10 (6.4),
19q13.11	ZNF507 (6.1)

Genes listed are those within each cytogenetic deletion or variation whose prioritization modelling based on known candidate genes and neurodevelopmental gene co-expression are predicted to have a similar loss of function phenotype. Some genes are in multiple regions as they overlap in the genome. Number in parentheses represents the **continuous connectivity score.** See Supplementary table 8 for full data set including references and data sources.

Figure 1. Genetic variant identification and variant filtering pipeline for individuals with CAS




Figure 2. Phenotype of individuals with CAS with (n=18) and without (n=52) high confidence pathogenic variants









Figure 3. Families with high-confidence variants analysed by genome sequencing
































Figure 4. Previously identified neurodevelopmental conditions in candidate genes for CAS






Figure 5. CAS candidate gene co-expression